Innovative Conceptual Idea: Human Bridge Pig. Liver Regeneration Method

This research paper examines the relationship between hepatitis infections and the development of liver cancer, a major cause of mortality in Hong Kong. It outlines the transmission pathways of hepatitis A, B, C, and E, and highlights medical advancements such as vaccination and biologic therapies that have significantly reduced infection rates and improved treatment outcomes. Despite these advances, liver cancer remains largely incurable, with current treatments primarily focused on symptom control rather than eliminating the underlying disease. The discussion reviews historical trends in hepatitis prevalence, particularly in Asia, and explores research efforts such as liver tissue studies conducted in Hong Kong. This paper also evaluates the role of biologic agents, including gamma globulin, in suppressing viral load and improving patient prognosis, while acknowledging the limitations of existing therapies in preventing progression to liver cancer. To address these challenges, the paper proposes an innovative stem cell–based therapeutic approach termed the “Human bridge Pig. Liver Implantation Method.” This innovative method involves harvesting healthy liver tissue, culturing it into functional liver cells, and implanting it to replace diseased tissue. Additionally, a novel bridging culture concept using animal organs, particularly pig liver, is introduced to enhance scalability and feasibility of liver regeneration while minimizing immune rejection. Our novel proposal builds on the liver’s natural regenerative capacity and draws parallels with existing tissue engineering practices. Although still theoretical and requiring further validation, these approaches suggest potential future directions for curative liver cancer treatment and regenerative medicine.